Skip to main content
. 2022 Jul 27;12:12821. doi: 10.1038/s41598-022-15050-8

Figure 1.

Figure 1

(A) The reported pharmacophoric features of EGFRIs. (B) Reported FDA EGFR inhibitors (Gefitinib and Erlotinib) and the synthesized compounds in this study (9a-p), as well as the binding mode of Erlotinib within EGFR active site.